NEWS

Contera Pharma, subsidiary of Bukwang, raised 51 billion KRW in Series B financing...

[June 30, 2020]

Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional investors. The size of the current round has increased more than 17-fold compared to series A financing in 2019. Contera, a Danish bioventure, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The company has several programs in its development pipelines, including the lead program, JM-010, which is currently under development for...

R&D

Contera Pharma, subsidiary of Bukwang, raised 51 billion KRW in Series B financing round

[June 30, 2020]

Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional...

PRODUCTS
COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...

|    ​Korean    |

7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square